Cediranib
Light Chain Deposition Disease
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Light Chain Deposition Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Brigham and Women's Hospital | Phase 3 | BB |
cc-5013 National Cancer Institute (NCI) | Phase 3 | B |
Thalidomide Margarida Magalhaes-Silverman | Phase 2 | B |
Inno-206 Margarida Magalhaes-Silverman | Phase 2 | B |
ETOPOSIDE Margarida Magalhaes-Silverman | Phase 2 | B |
View all 13 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →